Anzeige
Erschienen in:
02.06.2022 | Coronary Heart Disease (S. Virani and M. Al Rifai, Section Editors)
SGLT-2 Inhibitors for Patients with Heart Failure: What Have We Learned Recently?
Erschienen in: Current Atherosclerosis Reports | Ausgabe 8/2022
Einloggen, um Zugang zu erhaltenAbstract
Purpose of Review
In this review, we discuss the mechanisms of action of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and the purported protective effects for mitigating heart failure (HF)-related outcomes.
Recent Findings
Major randomized clinical trials have demonstrated the cardiovascular safety and efficacy of SGLT-2i among patients without known HF and those with established HF with reduced ejection fraction or preserved ejection fraction (HFrEF and HFpEF respectively). Recent HF guidelines have incorporated SGLT-2i in HF treatment algorithms.
Summary
SGLT-2i have emerged as a novel treatment for both prevention of HF and reduction of cardiovascular morbidity and mortality among patients with existing HFrEF or HFpEF.